دورية أكاديمية
Diabetes following SARS-CoV-2 infection: Incidence, persistence, and implications of COVID-19 vaccination. A retrospective cohort study of sixteen million people in England.
| العنوان: | Diabetes following SARS-CoV-2 infection: Incidence, persistence, and implications of COVID-19 vaccination. A retrospective cohort study of sixteen million people in England. |
|---|---|
| المؤلفون: | Taylor, Kirt, Eastwood, Sophie, Walker, Venexia, Cezard, Genevieve, Knight, Rochelle, Al Arab, Marwa, Wei, Yinghui, Horne, Elsie MF, Teece, Lucy, Forbes, Harriet, Walker, Alex, Fisher, Louis, Massey, Jon, Hopcroft, Lisa EM, Palmer, Tom, Coronado, Jose Cuitun, Ip, Samantha, Davy, Simon, Dillingham, Iain, Morton, Caroline, Greaves, Felix, Macleod, John, Goldacre, Ben, Wood, Angela, Chaturvedi, Nishi, Sterne, Jonathan AC, Denholm, Rachel |
| بيانات النشر: | Elsevier Department of Public Health and Primary Care, Cardiovascular Epidemiology Unit The Lancet Diabetes and Endocrinology |
| سنة النشر: | 2024 |
| المجموعة: | Apollo - University of Cambridge Repository |
| الوصف: | Background Type 2 diabetes (T2DM) incidence is increased after diagnosis of COVID-19. We investigated the the long-term effect of COVID-19 on the incidence of T2DM and other types of diabetes, and the impact of vaccination on the relationship. Methods With NHS England approval, we studied incident diabetes diagnoses following COVID-19 diagnosis in pre-vaccination (N=16,674,867, January 2020-December 2021), vaccinated (N =12,279,669), and unvaccinated (N=3,076,953) cohorts (June-December 2021), using linked electronic health records. We estimated adjusted hazard ratios (aHRs) comparing diabetes incidence post-COVID-19 diagnosis with incidence before or without diagnosis up to 102 weeks post-diagnosis. Results were stratified by COVID-19 severity (hospitalised/non-hospitalised) and diabetes type. Findings In the pre-vaccination cohort, aHRS for T2DM incidence after COVID-19 (compared to before or without diagnosis) declined from 4.30 (95% CI: 4.06,4.55) in weeks 1-4 to 1.24 (1.14,1.35) in weeks 53-102. aHRS were higher in unvaccinated than vaccinated people (8.76 (7.49,10.03)) versus 1.66 (1.50,1.84) in weeks 1-4) and for hospitalised COVID-19 (pre-vaccination cohort 28.3 (26.2,30.5) in weeks 1-4 declining to 2.04 (1.72,2.42) in weeks 53-102), than non-hospitalised COVID-19 (1.95 (1.78,2.13) in weeks 1-4, 1.11 (1.01,1.22) in weeks 53-102). T2DM persisted for 4 months after COVID-19 for ~60% of those diagnosed. Patterns were similar for Type 1 diabetes, though excess incidence did not persist beyond 6 months post-COVID-19 |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/369237Test; https://doi.org/10.17863/CAM.109122Test |
| DOI: | 10.17863/CAM.109122 |
| الإتاحة: | https://doi.org/10.17863/CAM.109122Test https://www.repository.cam.ac.uk/handle/1810/369237Test |
| حقوق: | Attribution 4.0 International ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.9FBC114D |
| قاعدة البيانات: | BASE |
| DOI: | 10.17863/CAM.109122 |
|---|